Registered number: 09272873
COMPANY INFORMATION
CONTENTS
CHAIRMAN'S STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
The chairman presents his statement for the year ended 31 December 2025.
I am pleased to report that the Group delivered another year of significant progress, building on the momentum of 2024. Despite the ongoing macroeconomic, commercial and political challenges facing the biotech sector — most notably the contraction of the mRNA vaccine market following policy decisions in the United States — the Group has continued to expand its customer base and reinforce its leadership in synthetic DNA manufacturing. We are encouraged by the significant advances being made in gene editing and non-viral gene therapy markets, which represent substantial and growing opportunities for our platform. This progress is reflected in the continued clinical adoption of our technology across multiple modalities, with 9 clinical programmes having received Investigational New Drug (IND) application acceptances to date, and a further 7 in progress.
Financially, the Group generated revenue of £11.0 million (FY2024: £16.6 million). Whilst licensing revenue in mRNA applications was most impacted by the broader market conditions and below expectations, the underlying CDMO business grew 97% to £9.6 million (FY2024: £4.9 million).
Furthermore, we continued to execute our commercial strategy, most notably through the successful closing of a landmark transaction with Ceva Animal Health (Ceva), the fifth-largest global animal health business. We completed the disposal of our Touchlight Aquaculture subsidiary to Ceva in return for £9.9m of proceeds to the Group, alongside entering into a licence agreement granting Ceva rights to develop and manufacture future products using our dbDNA™ technology within the animal health field. The partnership extends the reach of our technology and positions the Group to benefit from milestone payments and royalties supporting future growth and diversification.
Alongside this, we deepened our commercial reach through the Group’s agreement with New England Biolabs (NEB), a world leader in the discovery and production of enzymes and reagents for molecular biology, to jointly develop and market a cell-free dbDNA™ synthesis kit. This collaboration marks a significant step in broadening the accessibility of our technology, enabling researchers to synthesise doggybone™ DNA directly at the benchtop for the first time, without the need for traditional plasmid-based manufacturing. We are proud to deepen our partnership with NEB and believe this collaboration will accelerate the adoption of dbDNA™ as a platform of choice for nucleic acid therapeutic development.
In parallel with these commercial developments, we continued to invest in platform innovation. Most notably, we launched mbDNA™ as a best-in-class gene-editing template, supporting high Homology-Directed Repair (HDR) efficiency and expanded payloads for non-viral gene therapy. Following close behind, we expanded our platform further with the launch of new circular DNA architectures (sscDNA, hsscDNA and dscDNA), enhancing stability and efficiency for gene-editing and therapy applications. These innovations further differentiated our offering and provide Touchlight with new avenues to participate in gene therapy and advanced medicines.
These advances were underpinned by a major regulatory and operational milestone. Early in the year, we received GMP certification of our facility in Hampton, UK and became the first synthetic DNA manufacturer globally to gain regulatory approval to produce Active Pharmaceutical Ingredients (API) – a world-first GMP licence for cell-free DNA manufacturing that positions the Group as a trusted partner for global biopharma companies. The Morelands facility also received the 2025 ISPE Facility of the Year Award for Innovation, recognising our commitment to and achievement of establishing a facility that provides operational excellence and sustainability.
The Group also prevailed in the High Court, receiving judgment in its favour on all grounds in the previously reported intellectual property entitlement proceedings. The Court found comprehensively in the Group’s favour with all claims dismissed, without potential for appeal. This represents the outcome expected and brought a welcome conclusion to the matter.
To support the next phase of growth, we were pleased to welcome Will Downie as Strategic Adviser during the year, whose extensive experience as an industry leader will support the Group’s growth ambitions. Post-period, Will was appointed to the Board as a Non-Executive Director.
Financially, the Group generated revenue of £11.0 million (FY2024: £16.6 million). Whilst licensing revenue in mRNA applications was most impacted by the broader market conditions and below expectations, the underlying CDMO business grew 97% to £9.6 million (FY2024: £4.9 million).
Furthermore, we continued to execute our commercial strategy, most notably through the successful closing of a landmark transaction with Ceva Animal Health (Ceva), the fifth-largest global animal health business. We completed the disposal of our Touchlight Aquaculture subsidiary to Ceva in return for £9.9m of proceeds to the Group, alongside entering into a licence agreement granting Ceva rights to develop and manufacture future products using our dbDNA™ technology within the animal health field. The partnership extends the reach of our technology and positions the Group to benefit from milestone payments and royalties supporting future growth and diversification.
Alongside this, we deepened our commercial reach through the Group’s agreement with New England Biolabs (NEB), a world leader in the discovery and production of enzymes and reagents for molecular biology, to jointly develop and market a cell-free dbDNA™ synthesis kit. This collaboration marks a significant step in broadening the accessibility of our technology, enabling researchers to synthesise doggybone™ DNA directly at the benchtop for the first time, without the need for traditional plasmid-based manufacturing. We are proud to deepen our partnership with NEB and believe this collaboration will accelerate the adoption of dbDNA™ as a platform of choice for nucleic acid therapeutic development.
In parallel with these commercial developments, we continued to invest in platform innovation. Most notably, we launched mbDNA™ as a best-in-class gene-editing template, supporting high Homology-Directed Repair (HDR) efficiency and expanded payloads for non-viral gene therapy. Following close behind, we expanded our platform further with the launch of new circular DNA architectures (sscDNA, hsscDNA and dscDNA), enhancing stability and efficiency for gene-editing and therapy applications. These innovations further differentiated our offering and provide Touchlight with new avenues to participate in gene therapy and advanced medicines.
These advances were underpinned by a major regulatory and operational milestone. Early in the year, we received GMP certification of our facility in Hampton, UK and became the first synthetic DNA manufacturer globally to gain regulatory approval to produce Active Pharmaceutical Ingredients (API) – a world-first GMP licence for cell-free DNA manufacturing that positions the Group as a trusted partner for global biopharma companies. The Morelands facility also received the 2025 ISPE Facility of the Year Award for Innovation, recognising our commitment to and achievement of establishing a facility that provides operational excellence and sustainability.
The Group also prevailed in the High Court, receiving judgment in its favour on all grounds in the previously reported intellectual property entitlement proceedings. The Court found comprehensively in the Group’s favour with all claims dismissed, without potential for appeal. This represents the outcome expected and brought a welcome conclusion to the matter.
To support the next phase of growth, we were pleased to welcome Will Downie as Strategic Adviser during the year, whose extensive experience as an industry leader will support the Group’s growth ambitions. Post-period, Will was appointed to the Board as a Non-Executive Director.
Page 1
TOUCHLIGHT HOLDINGS LIMITED
CHAIRMAN'S STATEMENT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
We have built one of the largest DNA manufacturing facilities in the world and are maintaining our position as pioneers and leaders in synthetic DNA – a platform that affords benefits of speed, purity and control. We continue to look forward with confidence to delivering into the global DNA market.
J Ohlson
Chairman
Chairman
Date:
Page 2
BUSINESS HIGHLIGHTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Continuing progress as demonstrated by:
∙Hampton, UK facility receives GMP certification - Touchlight becomes the first synthetic DNA manufacturer globally to gain regulatory approval to produce Active Pharmaceutical Ingredient (API).
∙Disposal of Touchlight Aquaculture to Ceva Animal Health, with Ceva entering a parallel licence to be granted rights to develop and manufacture future products incorporating Touchlight’s dbDNA technology across the animal health field.
∙mbDNA™ launch – established as a best-in-class gene editing template, supporting high HDR efficiency and expanded payloads for non-viral gene therapy.
∙Expansion of mbDNA™ Platform – introduction of sscDNA, hsscDNA, and dscDNA architectures, enhancing stability and efficiency for gene editing and therapy applications.
∙ISPE Facility of the Year 2025 – Morelands facility named Category Winner for Innovation, recognising its transformation into the world’s largest cell-free DNA manufacturing site.
∙Clinical adoption – z-dbDNA™ selected for a pioneering gene therapy clinical study.
Financial highlights
∙Revenue of £11.0 million (FY24: £16.6 million).
∙Cash at year end of £4.9 million (FY24: £11.8 million).
∙Reported profit of £8.4 million (FY24: £15.3 million loss).
Post-period commercial developments
∙Launches EnClose™ Cell-free dbDNA™ Synthesis Kit, developed in collaboration with NEB. The kit enables the rapid benchtop synthesis of high-purity dbDNA™ in a single day, providing researchers with a scalable, cell-free alternative to plasmid DNA for the development of mRNA therapeutics, gene therapies, and viral vectors.
Page 3
GROUP STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The directors present their Group strategic report together with the audited financial statements for the year ended 31 December 2025.
The publication of the human genome in the early 2000s has driven an acceleration in medical advances, enabling a new era of therapies targeted at a range of diseases. Transformative therapies (AAV, lentivirus, cell therapy) are now used to manage previously untreatable conditions, including cancers and rare genetic diseases, and more recently the COVID-19 pandemic accelerated the use of nucleic acid therapies including mRNA and DNA.
Such advanced therapy relies upon DNA, making it the basis of genetic medicine. The global market for DNA is estimated to support more than 3,000 preclinical, clinical and commercial products and is presently worth approximately £600m p.a., expected to grow strongly to more than £2.6bn by 2032. Whilst these trends are highly positive, supply chain challenges remain an impediment to globalisation of genetic medicine, including the manufacture of DNA.
Such advanced therapy relies upon DNA, making it the basis of genetic medicine. The global market for DNA is estimated to support more than 3,000 preclinical, clinical and commercial products and is presently worth approximately £600m p.a., expected to grow strongly to more than £2.6bn by 2032. Whilst these trends are highly positive, supply chain challenges remain an impediment to globalisation of genetic medicine, including the manufacture of DNA.
The Group uses its proprietary intellectual property to provide synthetic DNA to be used in the development and manufacture of products supporting large-scale adoption of genetic medicine.
Touchlight's threefold strategy focuses on:
∙Driving innovation through the development of novel DNA manufacturing solutions;
∙Contributing to the development of ground-breaking medicines and their associated impact on a range of patient conditions; and
∙Delivering social benefit through cutting-edge technology, which in turn creates shareholder value.
These objectives are achieved through advancing market awareness and adoption of dbDNA™, mbDNA™, the Group's broad range of technology platforms; a state-of-the-art GMP-certified manufacturing facility; and a proprietary, patented and scaled DNA platform. Touchlight is well placed to address global DNA supply and to contribute to the advancement of cell and gene therapies.
Group revenue reached £11.0 million in the year (FY2024: £16.6 million). Whilst licensing revenue reduced — much of the prior-year figure reflecting one new licence agreement signed in 2024 — there was a year-on-year increase in the sale of CDMO goods and services of approximately 97%.
The Group recorded a profit for the year of £8.4 million (FY2024: £15.3 million loss), mostly benefiting from a fair value gain on financial instruments and a profit on disposal of Touchlight Aquaculture.
The Group closed the year with a cash balance of £4.9 million (FY2024: £11.8 million). The proceeds from the disposal of the subsidiary were consumed by operating activities.
Net liabilities closed at £46.6 million (FY2024: £55.9 million).
Further information about the Group's performance for the year is included in the Chairman's Statement on page 1.
Page 4
GROUP STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
This section lays out risks that are specific to the Touchlight business and those of a general nature, which either individually or collectively could affect the future operating and financial performance of Touchlight. Touchlight seeks to manage the risks to minimise the potential impact however several of these risks are outside the control of the business.
∙Product risk. To date our products are proving compelling to customers, however continuing market acceptance of Touchlight's range of products will depend both on potential customers finding the offerings more competitive than alternatives and Touchlight's continued ability to manufacture at scale. Touchlight seeks to mitigate this risk through constant contact with its customers and continued research, development and innovation.
∙Market risk. Touchlight operates in a dynamic and evolving sector where customer demand may be influenced by shifts in political environment, market sentiment, funding availability, regulatory changes, and competitor activity. A severe downturn in the biotech investment climate or changes in customer priorities could reduce demand for Touchlight’s products and services. The Company mitigates this risk through diversification of its customer base, strategic partnerships, and maintaining flexibility in its commercial offerings to adapt to changing market conditions.
∙Partnership risk. Touchlight is engaged in partnerships and licensing arrangements. Such arrangements will invariably expose the business to counterparty risk. Touchlight seeks to mitigate this risk through careful construction of partnership and licence agreements to minimise exposure and by ensuring adequate liquidity at the Group level.
∙Funding risk. The Group may need to raise money to fund its strategic objectives and growth initiatives. An inability to secure funding on acceptable terms, or at all, could constrain the Group's ability to deliver its growth plans. Touchlight seeks to mitigate this risk by carefully monitoring its cashflows and forecasts and adjusting spending and investment decisions accordingly. Certain of the Group's shareholders have also demonstrated their support by providing a Shareholder Loan Facility of up to £10.0 million which may be drawn upon until 31 March 2027 (£5.5 million of which has been drawn in 2026).
∙Dependence on key personnel. Touchlight is dependent on its scientific and management team. The loss (whether temporary or permanent) of these individuals could materially impact research and development activities. Touchlight seeks to mitigate this risk through competitive remuneration and succession planning.
∙Competition. The sector is characterised by ongoing and continuous technological innovation which in time may impact Touchlight. Touchlight seeks to mitigate this through constant monitoring of its competitors and continued investment in research, development and innovation.
∙Economic environment and market conditions. The operating costs of Touchlight may be affected by currency fluctuations, inflation, legislative and other future political decisions including the increasing use of global trade tariffs. Touchlight seeks to mitigate this through close monitoring of the cost base and the economic environment.
∙Group intellectual property. Touchlight is dependent on its intellectual property. Copying of this by competitors or successful challenges to it would materially impact the business. Touchlight seeks to mitigate this risk through extensive patent protection and legal defence as and when required.
The above list of risks is not exhaustive and other unforeseen risks may in the future impact on the performance of Touchlight's business.
The Group closed the year with net liabilities of £46.6 million (FY2024: £55.9 million) and a cash balance of £4.9 million (FY2024: £11.8 million), reflecting reduced headroom during the year. The net liabilities position arises principally from the preference shares and loan notes issued by the Group, neither of which falls due for repayment within the period covered by the directors' going concern assessment.
The directors have assessed the Group's ability to continue as a going concern for the period to 31 December 2027, being the period covered by management's cash flow forecasts and scenario analysis. In performing that assessment, the directors considered the Group's cash position, forecast trading performance and access to funding, including the Shareholder Loan Facility.
The Group's forecasts assume continued growth in CDMO revenues and the signing of new licence agreements. As these assumptions are not contractually committed and are dependent on future customer activity and market conditions, there is uncertainty regarding the timing and level of future cash receipts. The Group also remains reliant on the Shareholder Loan Facility, which may be drawn upon until 31 March 2027.
Page 5
GROUP STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
These conditions indicate the existence of a material uncertainty which may cast significant doubt on the Group's ability to continue as a going concern. Nevertheless, having considered the forecasts, scenario analysis, available funding and mitigating actions available to management, the directors continue to consider it appropriate to prepare the financial statements on a going concern basis. Further details are set out in note 2.4.
The key performance indicators ("KPI") are:
∙The closing cash balance, which was £4.9 million at 31 December 2025 (FY2024: £11.8 million).
∙Revenue in the year, which was £11.0 million (FY2024: £16.6 million).
∙Net profit in the year, which was £8.4 million (FY2024: £15.3 million loss).
In accordance with Section 172 of the Companies Act 2006, the Directors of the Group must act in a way that they, in good faith, would be most likely to promote the success of the Group for the benefit of its members as a whole and in doing so the Directors have had regard to, their workforce, stakeholders, community and environment and business conduct. This statement is made voluntarily.
This report was approved by the board and signed on its behalf.
Page 6
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
The directors present their report and the financial statements for the year ended 31 December 2025.
The directors who served during the year were:
The directors are responsible for preparing the Group strategic report, the Directors' report and the consolidated financial statements in accordance with applicable law and regulations.
In preparing these financial statements, the directors are required to:
∙select suitable accounting policies for the Group's financial statements and then apply them consistently;
∙make judgments and accounting estimates that are reasonable and prudent;
∙state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
∙prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and the Group and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The profit for the year, after taxation, amounted to £8,354,449 (2024: loss £15,293,483).
The directors do not recommend payment of a dividend.
For more detail on future business development, please refer to the Chairman’s Statement and the Business Highlights sections.
Page 7
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
The Group has chosen, in accordance with Section 414C(11) of the Companies Act 2006 (Strategic Report and Directors' Report) Regulations 2013, to set out within the Group's Strategic Report the Company's Strategic Report Information Required by Schedule 7 of the Large and Medium Sized Companies and Groups (Accounts and Reports) Regulation 2008. This includes information that would have been included in the business review and details of the principal risks and uncertainties.
Subsequent to the balance sheet date, the Company drew down £5,500,000 under its existing shareholder loan facility to provide additional working capital funding for the Group’s operations.
In addition, the Group received a milestone payment of £5,000,000 under its collaboration agreement with Ceva, following the achievement of a contractual milestone.
In addition, the Group received a milestone payment of £5,000,000 under its collaboration agreement with Ceva, following the achievement of a contractual milestone.
Under section 487(2) of the Companies Act 2006, Deloitte LLP will be deemed to have been reappointed as auditors 28 days after these financial statements were sent to members or 28 days after the latest date prescribed for filing the financial statements with the registrar, whichever is earlier.
This report was approved by the board and signed on its behalf.
Page 8
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF TOUCHLIGHT HOLDINGS LIMITED
In our opinion the financial statements of Touchlight Holdings Limited (the 'parent Company') and its subsidiaries (the 'Group'):
∙give a true and fair view of the state of the group’s affairs as at 31 December 2025 and of its profit for the year then
∙ended;
∙have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, including Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”; and
∙have been prepared in accordance with the requirements of the Companies Act 2006.
We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
We draw attention to note 2.4 in the financial statements, which describes the uncertain trading environment, and the group’s dependence on the Shareholder Loan Facility until 31 March 2027, and on the need to obtain further funding thereafter. As stated in note 2.4, these events or conditions indicate that a material uncertainty exists that may cast significant doubt on the Group’s and the parent company’s ability to continue as a going concern. Our opinion is not modified in respect of this matter.
In auditing the financial statements, we have concluded that the directors’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Page 9
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF TOUCHLIGHT HOLDINGS LIMITED (CONTINUED)
The other information comprises the information included in the annual report other than the financial statements and our Auditors' report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
As explained more fully in the directors’ responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the Group’s and the parent company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or the parent company or to cease operations, or have no realistic alternative but to do so.
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements..
A further description of our responsibilities for the audit of the financial statements is located on the FRC’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
Page 10
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF TOUCHLIGHT HOLDINGS LIMITED (CONTINUED)
We obtained an understanding of the legal and regulatory frameworks that the group operates in, and identified the key laws and regulations that:
Page 11
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF TOUCHLIGHT HOLDINGS LIMITED (CONTINUED)
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the strategic report and the directors’ report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the strategic report and the directors’ report have been prepared in accordance with applicable legal requirements.
In the light of the knowledge and understanding of the group and its environment obtained in the course of the audit, we have not identified any material misstatements in the strategic report or the directors’ report.
Matters on which we are required to report by exception
Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:
∙adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
∙the financial statements are not in agreement with the accounting records and returns; or
∙certain disclosures of directors’ remuneration specified by law are not made; or
∙we have not received all the information and explanations we require for our audit.
We have nothing to report in respect of these matters.
Page 12
INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF TOUCHLIGHT HOLDINGS LIMITED (CONTINUED)
This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members, as a body, for our audit work, for this report, or for the opinions we have formed.
for and on behalf of
Statutory Auditor
Cambridge, United Kingdom
Statutory Auditor
Page 13
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 31 DECEMBER 2025
Page 14
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 23 to 49 form part of these financial statements.
Page 15
COMPANY STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 23 to 49 form part of these financial statements.
Page 16